Inês Mota Postdoctoral Associate in Radiation Oncology

Postdoctoral Associate in Radiation Oncology, Radiation Oncology , Weill Cornell Medical College 2021 -
Fellow in Radiation Oncology, Radiation Oncology , Weill Cornell Medical College 2021 - 2021

Publications

Sort by

Co-Author Network

ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer cell. 2023 Academic Article GET IT
ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer. Nature cancer. 2023 Academic Article GET IT
Times cited: 18
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma. Science translational medicine. 2023 Academic Article GET IT
Tyrosine phosphatases regulate resistance to ALK inhibitors in ALK+ anaplastic large cell lymphoma. Blood. 2022 Academic Article GET IT
Times cited: 17
Comment on "ALK is a therapeutic target for lethal sepsis". Science translational medicine. 2018 Comment GET IT
Times cited: 5
Wiskott-Aldrich syndrome protein (WASP) is a tumor suppressor in T cell lymphoma. Nature medicine. 2018 Academic Article GET IT
Times cited: 50
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. Cancers. 2018 Review GET IT
Times cited: 76

Sort by

Co-investigator Network

Therapeutic targeting of breast cancer and host immune responses at inflection points in the disease trajectory awarded by United States Department of Defense Key Personnel 2021 - 2025
Converting HR Breast Cancer Into an Individualized Vaccine awarded by United States Department of Defense Key Personnel 2019 - 2024
Converting HR+ Breast Cancer Into an Individualized Vaccine awarded by United States Department of Defense Key Personnel 2019 - 2024